Mindray Announces Second Quarter 2014 Financial Results

Mindray Announces Second Quarter 2014 Financial Results

Highlights for Second Quarter 2014

• Net revenues increased 8.9% year-over-year to $334.5 million. International sales were $182.0 million, representing 54.4% of the company's total net revenues. China sales totaled $152.5 million.
• Reagent sales contributed 41.2% to the IVD segment, up from 36.6% in the same period last year and from 38.1% in the previous quarter.
• In addition to the reagents, the biochemistry analyzers BS-800 and BS-2000 performed well in China.

"In the second quarter, the Chinese healthcare market remained sluggish for our business while unfavorable foreign exchange and political issues affected our sales in some key emerging markets," commented Mr. Li Xiting, Mindray's President and Co-Chief Executive Officer. "However, we are encouraged by our reagent sales performance and the growth momentum achieved by our high-speed biochemistry analyzers and high-end ultrasound products. This is the result of our focus on innovation, which allows us to consistently introduce new products into different markets."

(Extract from mindray)